Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | HRH2 | P25021 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27796930 | 0.87 | CYP2D6 (0.53) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL11096825 | 0.87 | CYP3A4 (0.52) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| Hydrochloric Acid SCHEMBL7452248 | 0.85 | CYP2D6 (0.52) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL14129958 | 0.84 | CYP2D6 (1.00) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL11093336 | 0.80 | KCNA3 (0.52) | CYP2D6KDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL31621357 | 0.79 | CYP2D6 (0.89) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL9650447 | 0.79 | CYP2D6 (0.89) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL9804775 | 0.79 | CYP2D6 (0.66) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL31621352 | 0.79 | CYP2D6 (0.89) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 | |
| SCHEMBL14901529 | 0.79 | ALDH1A1 (0.56) | CYP2D6CYP3A4NPC1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| CN-101258138-B | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV | 2013-06-12 | — | — | CN | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| CN-101258138-A | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV (FR) | 2008-09-03 | — | — | CN | disclosed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717235-A2 | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH1 | CYP2D6 1736/4885CYP3A4 2341/4885NPC1 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.